21,866 Shares in Apellis Pharmaceuticals, Inc. $APLS Acquired by PSP Research LLC

PSP Research LLC purchased a new position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 21,866 shares of the company’s stock, valued at approximately $549,000. Apellis Pharmaceuticals accounts for 0.5% of PSP Research LLC’s holdings, making the stock its 11th largest position.

Several other hedge funds and other institutional investors have also modified their holdings of APLS. AQR Capital Management LLC boosted its holdings in shares of Apellis Pharmaceuticals by 46.6% in the second quarter. AQR Capital Management LLC now owns 5,976,414 shares of the company’s stock valued at $103,452,000 after acquiring an additional 1,898,995 shares in the last quarter. Polar Capital Holdings Plc boosted its holdings in shares of Apellis Pharmaceuticals by 96.0% in the third quarter. Polar Capital Holdings Plc now owns 2,650,230 shares of the company’s stock valued at $59,975,000 after acquiring an additional 1,298,055 shares in the last quarter. Millennium Management LLC boosted its holdings in shares of Apellis Pharmaceuticals by 563.7% in the third quarter. Millennium Management LLC now owns 1,343,726 shares of the company’s stock valued at $30,409,000 after acquiring an additional 1,141,274 shares in the last quarter. Deep Track Capital LP boosted its holdings in shares of Apellis Pharmaceuticals by 14.3% in the third quarter. Deep Track Capital LP now owns 8,000,382 shares of the company’s stock valued at $181,049,000 after acquiring an additional 1,000,382 shares in the last quarter. Finally, ING Groep NV boosted its holdings in shares of Apellis Pharmaceuticals by 281.0% in the third quarter. ING Groep NV now owns 1,174,500 shares of the company’s stock valued at $26,579,000 after acquiring an additional 866,200 shares in the last quarter. 96.29% of the stock is currently owned by hedge funds and other institutional investors.

Apellis Pharmaceuticals Price Performance

APLS stock opened at $41.03 on Wednesday. Apellis Pharmaceuticals, Inc. has a 12-month low of $16.10 and a 12-month high of $41.14. The company has a quick ratio of 3.16, a current ratio of 3.63 and a debt-to-equity ratio of 0.87. The company has a market cap of $5.25 billion, a price-to-earnings ratio of 40.23 and a beta of -0.24. The company has a 50 day moving average of $33.61 and a two-hundred day moving average of $26.28.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its earnings results on Thursday, May 7th. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.44. Apellis Pharmaceuticals had a net margin of 12.06% and a return on equity of 39.71%. The company had revenue of $268.30 million during the quarter, compared to the consensus estimate of $208.91 million. On average, equities analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.14 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

APLS has been the subject of a number of research reports. Cantor Fitzgerald restated a “neutral” rating on shares of Apellis Pharmaceuticals in a report on Friday, May 15th. Wedbush reduced their target price on shares of Apellis Pharmaceuticals from $20.00 to $18.00 and set a “neutral” rating for the company in a report on Wednesday, February 25th. Royal Bank Of Canada reduced their target price on shares of Apellis Pharmaceuticals from $22.00 to $21.00 and set a “sector perform” rating for the company in a report on Wednesday, February 25th. JPMorgan Chase & Co. restated a “neutral” rating and set a $41.00 target price (up from $37.00) on shares of Apellis Pharmaceuticals in a report on Wednesday, April 1st. Finally, William Blair cut shares of Apellis Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 31st. Three equities research analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $35.72.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.